XOMA Royalty Corp
XOMA
查看详细走势图
24.860USD
-0.060-0.24%
收盘 02/06, 16:00（美东）报价延迟15分钟
306.03M总市值
30.63市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.24%
5天
-3.12%
1月
-16.91%
6月
-6.19%
今年开始到现在
-6.51%
1年
-2.70%
查看详细走势图
TradingKey XOMA Royalty Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
XOMA Royalty Corp当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在媒体与出版行业排名36/76位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价64.50。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
XOMA Royalty Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
XOMA Royalty Corp亮点
亮点风险
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
业绩高增长
公司营业收入稳步增长，连续3年增长372.66%
业绩增长期
公司处于发展阶段，最新年度总收入28.49M美元
估值高估
公司最新PE估值30.63，处于3年历史高位
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值2.66K
分析师目标
根据
4
位分析师
买入
评级
64.500
目标均价
+159.45%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
XOMA Royalty Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
XOMA Royalty Corp简介
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
公司代码XOMA
公司XOMA Royalty Corp
CEOMr. Owen P. Hughes, Jr.
网址https://xoma.com/
相关品种
+1.14%
+3.55%
+0.31%
+3.52%
+6.72%
+2.08%
+1.83%
+2.24%
+2.44%
+1.14%
+8.08%
+1.51%
+3.57%
+6.56%
+1.85%
+0.80%
+2.40%
-1.73%
+2.05%
+1.27%
